Several MKIs that were approved by FDA for cancer therapy on other purposes (such as sunitinib, sorafenib, vandetanib, cabozantinib, regorafenib, lenvatinib, and alectinib) all showed modest clinical activity and had side effects for patients with RET fusion-positive NSCLC (Drilon et al. 2016, 2018, 2019; Gautschi et al. 2017; Yoh et al. 2017; Ribeiro et al. 2020). The gene discussed is RET; the disease is non-small cell lung carcinoma.